Page last updated: 2024-11-08

isofloridoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

isofloridoside: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isofloridoside : A galactosylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding alpha-D-galactopyranoside. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID193395
CHEBI ID147787
MeSH IDM0084090

Synonyms (10)

Synonym
isofloridoside
CHEBI:147787
2,3-dihydroxypropyl alpha-d-galactopyranoside
3-o-galactopyranosylglycerol
wurcs=2.0/2,2,1/[hxh][a2112h-1a_1-5]/1-2/a3-b1
4649-46-1
(2s,3r,4s,5r,6r)-2-(2,3-dihydroxypropoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
3-o-galactopyranosyl-sn-glycerol
d-glyceryl beta-galactopyranoside
alpha-d-galactopyranosyl-(1-1)-glycerol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
alpha-D-galactosideAny D-galactoside having alpha-configuration at its anomeric centre.
galactosylglycerolA glycosylglycerol in which the glycosyl residue specified is galactose.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (15.38)18.7374
1990's1 (7.69)18.2507
2000's3 (23.08)29.6817
2010's5 (38.46)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]